Surgeon Volume Outcomes: 5 Critical Practice Considerations
Original evidence synthesis on how surgeon and hospital volume influence cancer surgery outcomes, the measurable impact of formal accreditation programs, and the regional variation that persists despite a generation of centralization policy.
One-Minute Takeaway on Surgeon Volume Outcomes
The bottom line in five bullets:
- Surgeon volume outcomes data show the strongest, most reproducible effects for complex cancer operations — pancreaticoduodenectomy, esophagectomy, and lung resection — where high-volume centers report 30 to 60 percent lower operative mortality than low-volume centers.
- For common cancer operations (colectomy, mastectomy, prostatectomy), surgeon volume outcomes effects are real but modest, and the marginal benefit narrows substantially above mid-range volume thresholds.
- National centralization programs in the Netherlands, Denmark, and the UK have produced measurable mortality reductions; spontaneous centralization in the US has done much the same for esophageal surgery without consistently widening rural-urban gaps.
- Commission on Cancer accreditation correlates with better survival across several cancer sites, but selection effects, hospital size, and case-mix differences make causal attribution to accreditation itself difficult.
- Regional variation in surgeon volume outcomes persists, with travel burden, workforce concentration, and rural hospital viability creating real tradeoffs that any volume-based policy must address.
Why Surgeon Volume Outcomes Still Matter in Modern Cancer Surgery
The relationship between procedural volume and surgical mortality has been one of the most consistently reproduced findings in health services research. Landmark Medicare analyses two decades ago documented striking surgeon volume outcomes gradients across complex cancer operations, and the pattern has since been replicated in national datasets across Europe, Asia, and North America.
The surgical community responded. Voluntary regionalization, minimum-volume policies, accreditation programs, and outright national centralization have reshaped where cancer surgery happens. In several European countries, esophagectomy and pancreaticoduodenectomy have been concentrated into a handful of designated centers. In the US, payer pressure and Leapfrog standards have steered cases toward higher-volume hospitals.
Yet the surgeon volume outcomes question is far from closed. Centralization brings access tradeoffs and travel burden. Accreditation effects are entangled with selection bias. Modern team-based perioperative care, enhanced recovery protocols, and minimally invasive techniques may have changed how strongly individual surgeon volume drives outcomes today.
This evidence review asks where the surgeon volume outcomes literature now stands — what it strongly supports, what it cautiously suggests, and what remains unresolved after twenty-five years of investigation.
Evidence Reviewed on Surgeon Volume Outcomes
The synthesis below draws on twelve key studies spanning national registry analyses, systematic reviews, contemporary meta-analyses, and population-based evaluations of accreditation and centralization. Studies were selected for methodological rigor, sample size, and direct relevance to cancer surgery outcomes.
| Study (first author, year) | Design | Setting / N | Key surgeon volume outcomes finding |
|---|---|---|---|
| Birkmeyer NEJM 2002 | Medicare cohort | US; 2.5 million procedures | Hospital volume inversely related to mortality across 14 high-risk operations; largest effects in pancreatic and esophageal resection |
| Birkmeyer NEJM 2003 | Medicare cohort | US; 474,108 patients | Surgeon volume independently predicted operative mortality after adjustment for hospital volume; explained much of hospital-level effect |
| Halm Ann Intern Med 2002 | Systematic review | 135 studies, 27 procedures | Higher volume associated with better outcomes for most procedures; effect strongest for cancer resections and cardiovascular surgery |
| Finks NEJM 2011 | Repeat Medicare cohort | US; 8 procedures, 2000–2009 | Volume-mortality association weakened over time for several procedures; persisted for pancreatic and esophageal cancer |
| von Meyenfeldt J Thorac Oncol 2012 | Systematic review & meta-analysis | 19 studies, lung cancer surgery | Hospital volume more important than surgeon volume; surgeon specialty (thoracic vs general) showed independent effect |
| Gooiker Br J Surg 2011 | Systematic review & meta-analysis | 14 high-quality pancreatic studies | Strong inverse association between hospital volume and pancreatic surgery mortality; the most robust example in the literature |
| Huo J Gastrointest Oncol 2017 | Systematic review & meta-analysis | 47 colorectal cancer studies | Volume association present but non-linear; modest effect compared with complex resections |
| Trinh JCO 2013 / NCDB rectal analyses | National registry cohort | 7,798 rectal resections | High-volume surgeons at high-volume hospitals: 57% lower mortality (OR 0.43, 95% CI 0.21–0.87) |
| Stitzenberg JCO 2009 | SEER-Medicare | US; 5 cancer operations | Centralization increased mean travel distance; access concerns concentrated among older, rural, lower-income patients |
| Schlottmann Ann Surg Oncol 2018 | NIS cohort | US esophagectomy, 2000–2014 | Spontaneous centralization reduced mortality without widening rural-urban disparities |
| Hashimoto Ann Surg Oncol 2024 | SEER analysis | 800,677 cancer cases (CoC vs non-CoC) | CoC accreditation associated with improved survival for several cancers; effect attenuates with adjustment |
| Aiolfi Ann Surg Oncol 2025 | Individual patient data meta-analysis | 23,194 esophagectomies, 9 studies | High-volume centers: 4.3 months greater mean survival at 5 years; consistent across subgroups |
Key Findings on Surgeon Volume Outcomes by Cancer Type and Setting
Pancreatic and Esophageal Resection: The Strongest Surgeon Volume Outcomes Effects
Across more than a hundred studies, pancreaticoduodenectomy stands out as the operation with the most reproducible volume-outcome gradient. Pooled meta-analytic data and national registry studies converge on a consistent finding: high-volume centers report perioperative mortality of 2 to 4 percent, compared with 8 to 15 percent at low-volume centers. The dose-response curve plateaus, but the contrast remains striking.
Contemporary work using restricted cubic splines suggests the maximum improvement in 90-day mortality occurs once hospital volume exceeds approximately 9 cases per year, with further gains observed up to roughly 35–60 cases annually. For minimally invasive pancreaticoduodenectomy, an even higher threshold (around 20 cases per year) appears necessary to match open-surgery safety profiles.
Esophagectomy shows a closely parallel pattern. The 2025 individual patient data meta-analysis of 23,194 patients across nine studies found that surgery in high-volume centers was associated with 4.3 months greater mean overall survival at five years. Surgeon volume outcomes data for esophageal cancer thus extend beyond perioperative safety to long-term oncologic results.
Lung, Rectal, and Hepatic Resections: Moderate and Specialty-Dependent
For lung cancer surgery, hospital volume appears to drive outcomes more than individual surgeon volume, though surgeon specialty (thoracic-trained versus general thoracic) carries an independent effect. Volume thresholds reported in the literature vary but typically cluster around 20–50 anatomic resections per center per year.
Rectal cancer follows a similar pattern. National Cancer Database analyses show that combined high-volume surgeon and high-volume hospital care reduces operative mortality and non-restorative proctectomy rates. The combined effect (OR 0.43 for mortality) substantially exceeds either factor alone.
Common Cancer Operations: Real But Smaller Surgeon Volume Outcomes Effects
For colectomy, mastectomy, and radical prostatectomy, surgeon volume outcomes data are less dramatic. A meta-analysis of meta-analyses concluded that only a small number of procedures — pancreaticoduodenectomy chief among them — demonstrated convincing evidence of a surgeon volume-mortality relationship. For more common operations, the signal was weak or non-significant.
This does not mean volume is irrelevant for common cancers. Functional outcomes, recurrence rates, lymph node yields, and readmissions may still vary by volume. But the perioperative mortality differences that justify centralization for complex cancer surgery are much harder to demonstrate for routine cancer operations.
Centralization Programs: Real Mortality Gains, Predictable Tradeoffs
Programmed centralization in the Netherlands, Denmark, and the UK has produced measurable improvements. Dutch esophagectomy mortality fell substantially after volume standards concentrated cases in fewer centers. US data on esophageal cancer surgery show similar gains from spontaneous centralization, achieved without significant widening of rural-urban disparities for that specific procedure.
However, evaluations of centralization in colorectal cancer and bariatric surgery are more equivocal. A 2020 umbrella review of meta-analyses concluded that centralization policy should be applied selectively, with stronger evidence supporting it for pancreatic resection than for procedures with weaker volume signals.
Hospital Volume vs Surgeon Volume Outcomes: Disentangling the Two
A persistent question is whether the surgeon or the hospital matters more. Birkmeyer’s 2003 analysis suggested surgeon volume explained much of the apparent hospital effect, particularly for pancreatic resection. Subsequent work has nuanced this: for esophagectomy and lung resection, hospital infrastructure (ICU, interventional radiology, failure-to-rescue capacity) appears more important than individual surgeon caseload.
The pragmatic synthesis is that the best surgeon volume outcomes are seen when a high-volume surgeon operates within a high-volume hospital ecosystem. The combination is more than additive; each component supports the other through case selection, anesthesia experience, nursing familiarity, and rescue capacity.
Quality and Consistency of Surgeon Volume Outcomes Evidence
The evidence base is broad but methodologically uneven. Almost all studies are observational, drawing on national administrative or registry data. Randomization of patients to high- versus low-volume surgeons is not feasible. This creates inherent susceptibility to selection bias, residual confounding by case mix, and unmeasured hospital-level differences.
What Surgeon Volume Outcomes Research Has Not Shown
Specific Knowledge Gaps
- Optimal volume thresholds for most cancer operations remain undefined. Pancreaticoduodenectomy aside, surgeon volume outcomes data do not converge on specific case-per-year cutoffs that policy could enforce. Restricted cubic splines suggest different thresholds depending on outcome (90-day mortality, oncologic adequacy, readmission, functional recovery).
- The mechanism behind surgeon volume outcomes effects is not isolated. Is the benefit driven by technical skill, case-selection bias, perioperative team experience, or failure-to-rescue capacity? Without dismantling these, it is unclear which features of high-volume care travel to other settings.
- Long-term oncologic outcomes are less well studied than perioperative mortality. Many studies stop at 30 or 90 days. Whether high-volume care durably improves survival across the full follow-up period is supported for esophagectomy but inconsistent for other cancers.
- Effects of accreditation isolated from volume are poorly characterized. CoC-accredited hospitals tend to be larger, urban, and higher-volume. Disentangling the accreditation signal from the volume signal requires designs few studies have used.
- Travel burden, financial toxicity, and continuity-of-care harms from centralization are inconsistently measured. Mortality improvements may come at unmeasured cost to caregivers, postoperative follow-up, and rural workforce sustainability.
- Whether centralization improves equity or worsens it depends on which procedure and which population is studied. The evidence is genuinely mixed and resists a single answer.
Practical Implications of Surgeon Volume Outcomes Data
The volume-outcome literature supports several evidence-based considerations for clinicians, referring physicians, and institutions. These are framed as what the surgeon volume outcomes evidence supports, not as directive recommendations.
Evidence Supports Referral of Pancreaticoduodenectomy to High-Volume Centers
The reproducibility and magnitude of the surgeon volume outcomes signal for pancreatic resection is the strongest in the entire literature. Centers performing fewer than approximately 10 cases annually consistently report higher perioperative mortality.
Evidence Supports Centralization of Esophagectomy
Recent individual patient data meta-analysis supports a meaningful long-term survival advantage in high-volume centers. National centralization programs have produced measurable mortality reductions.
Surgeon Specialty May Matter as Much as Caseload for Lung Resection
Thoracic-trained surgeons show outcomes advantages independent of raw caseload. Policy that emphasizes only volume thresholds may miss this specialty effect.
CoC Accreditation Correlates with Improved Cancer Survival
Patients treated at Commission on Cancer-accredited facilities have better outcomes for several cancer sites, though selection effects mean accreditation should not be assumed to be the causal driver.
Regional Variation Requires Context-Specific Policy
Travel burden, rural hospital viability, and continuity-of-care concerns mean that surgeon volume outcomes data should inform — not dictate — referral patterns. Patient values and access matter alongside volume.
Combined High-Volume Surgeon and Hospital Show the Strongest Effect
For complex cancer resection, the combination of an experienced surgeon and a high-volume institution produces outcomes superior to either factor alone, likely through better failure-to-rescue capacity.
Context
Based on the current evidence, surgeon volume outcomes data remain one of the most actionable findings in surgical health services research. The strength of the recommendation should track the strength of the underlying signal, which varies substantially by procedure.
Evidence Grade and Bottom Line on Surgeon Volume Outcomes
Evidence Grade: Moderate to Strong (procedure-dependent)
The surgeon volume outcomes literature rests on consistent, large observational datasets and multiple meta-analyses. For pancreaticoduodenectomy and esophagectomy, the evidence is strong and the conclusions are unlikely to reverse. For lung and rectal cancer surgery, the evidence is moderate. For common cancer operations, the evidence is mixed and the magnitude of effect is smaller. No randomized trial of centralized versus distributed cancer surgical care exists, and the evidence is unlikely ever to come from such a design.
Bottom Line
- Surgeon volume outcomes data continue to support centralization of pancreaticoduodenectomy and esophagectomy, where the volume-mortality gradient is largest and most reproducible.
- For most other cancer operations, the volume signal is real but smaller, and policy should weight it against access and travel burden.
- Commission on Cancer accreditation correlates with improved outcomes but should not be treated as a causal substitute for volume itself.
- Regional disparities in surgeon volume outcomes persist and are unlikely to resolve through centralization alone; rural workforce, transportation, and care coordination policies are necessary complements.
- Clinicians should integrate the evidence by procedure: strong for complex resection, moderate for thoracic and rectal, weak for routine cancer operations.
Article Information and References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
This evidence review was developed to summarize the published surgeon volume outcomes literature relevant to cancer surgery. Selection of studies emphasized methodological rigor, sample size, geographic diversity, and recency. The synthesis aims for an honest representation of certainty: strong where the data are consistent, cautious where the data are mixed.
References
- Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–1137. DOI: 10.1056/NEJMsa012337
- Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349(22):2117–2127. DOI: 10.1056/NEJMsa035205
- Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature. Ann Intern Med. 2002;137(6):511–520. DOI: 10.7326/0003-4819-137-6-200209170-00012
- Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128–2137. DOI: 10.1056/NEJMsa1010705
- von Meyenfeldt EM, Gooiker GA, van Gijn W, et al. The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol. 2012;7(7):1170–1178. DOI: 10.1097/JTO.0b013e318257cc45
- Gooiker GA, van Gijn W, Wouters MWJM, Post PN, van de Velde CJH, Tollenaar RAEM. Systematic review and meta-analysis of the volume-outcome relationship in pancreatic surgery. Br J Surg. 2011;98(4):485–494. DOI: 10.1002/bjs.7413
- Huo YR, Phan K, Morris DL, Liauw W. Systematic review and a meta-analysis of hospital and surgeon volume/outcome relationships in colorectal cancer surgery. J Gastrointest Oncol. 2017;8(3):534–546. DOI: 10.21037/jgo.2017.01.25
- Stitzenberg KB, Sigurdson ER, Egleston BL, Starkey RB, Meropol NJ. Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol. 2009;27(28):4671–4678. DOI: 10.1200/JCO.2008.20.1715
- Schlottmann F, Strassle PD, Charles AG, Patti MG. Esophageal cancer surgery: spontaneous centralization in the US contributed to reduce mortality without causing health disparities. Ann Surg Oncol. 2018;25(6):1580–1587. DOI: 10.1245/s10434-018-6339-3
- Diaz A, Pawlik TM. Rural versus urban cancer care: unpacking the centralization dilemma and the impact of the COVID-19 pandemic. JCO Oncol Pract. 2024;20(1):1–3. DOI: 10.1200/OP.23.00679
- Bilimoria KY, Bentrem DJ, Feinglass JM, et al. Directing surgical quality improvement initiatives: comparison of perioperative mortality and long-term survival for cancer surgery. J Clin Oncol. 2008;26(28):4626–4633. DOI: 10.1200/JCO.2007.15.6356
- Aiolfi A, Bona D, De Bernardi S, et al. Impact of centralizing esophageal cancer surgery at high-volume centers on long-term survival: individual patient data meta-analysis. Ann Surg Oncol. 2025;32:7891–7900. DOI: 10.1245/s10434-025-17823-7